Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer

Immune checkpoint inhibitor (ICI) treatment has been used to treat advanced urothelial cancer. Molecular markers might improve risk stratification and prediction of ICI benefit for urothelial cancer patients. We analyzed 406 cases of bladder urothelial cancer from The Cancer Genome Atlas (TCGA) data...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pengju, Hao, Shihui, Ye, Yongkang, Wei, Jinhuan, Tang, Yiming, Tan, Lei, Liao, Zhuangyao, Zhang, Mingxiao, Li, Jiaying, Gui, Chengpeng, Xiao, Jiefei, Huang, Yong, Chen, Xu, Cao, Jiazheng, Luo, Junhang, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012532/
https://www.ncbi.nlm.nih.gov/pubmed/33816497
http://dx.doi.org/10.3389/fcell.2021.646982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012532/
https://www.ncbi.nlm.nih.gov/pubmed/33816497
http://dx.doi.org/10.3389/fcell.2021.646982

Ejemplares similares